Bacillus clausii for the treatment of acute diarrhea in children

A systematic review and meta-analysis of randomized controlled trials

Gianluca Ianiro, Gianenrico Rizzatti, Manuel Plomer, Loris Lopetuso, Franco Scaldaferri, Francesco Franceschi, Giovanni Cammarota, Antonio Gasbarrini

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Acute diarrhea is a burdensome disease with potentially harmful consequences, especially in childhood. Despite its large use in clinical practice, the efficacy of the probiotic Bacillus clausii in treating acute childhood diarrhea remains unclear. Our objective was to systematically review the efficacy of Bacillus clausii in the treatment of acute childhood diarrhea. The following electronic databases were systematically searched up to October 2017: MEDLINE (via PubMed/OVID), EMBASE (via OVID), Cochrane Central Database of Controlled Trials (via CENTRAL), Google Scholar, and ClinicalTrials.gov. Only randomized controlled trials were included. The overall effect for the meta-analysis was derived by using a random effects model. Six randomized controlled trials (1298 patients) met the eligibility criteria. Data arising from pooled analysis showed that Bacillus clausii significantly reduced the duration of diarrhea (mean difference = −9.12 h; 95% confidence interval [CI]: −16.49 to −1.75, p = 0.015), and the duration of hospitalization (mean difference = −0.85 days; 95% CI: −1.56 to −0.15, p = 0.017), compared with control. There was a trend of decreasing stool frequency after Bacillus clausii administration compared with the control group (mean difference = −0.19 diarrheal motions; 95% CI: −0.43 to −0.06, p = 0.14). Bacillus clausii may represent an effective therapeutic option in acute childhood diarrhea, with a good safety profile.

Original languageEnglish
Article number1074
JournalNutrients
Volume10
Issue number8
DOIs
Publication statusPublished - Aug 12 2018

Fingerprint

Bacillus clausii
systematic review
meta-analysis
Meta-Analysis
Diarrhea
diarrhea
Randomized Controlled Trials
childhood
confidence interval
Confidence Intervals
Databases
Therapeutics
duration
Probiotics
PubMed
MEDLINE
probiotics
electronics
Hospitalization
Safety

Keywords

  • Acute diarrhea
  • Bacillus clausii
  • Children
  • Efficacy
  • Randomized controlled trials

ASJC Scopus subject areas

  • Food Science
  • Nutrition and Dietetics

Cite this

Bacillus clausii for the treatment of acute diarrhea in children : A systematic review and meta-analysis of randomized controlled trials. / Ianiro, Gianluca; Rizzatti, Gianenrico; Plomer, Manuel; Lopetuso, Loris; Scaldaferri, Franco; Franceschi, Francesco; Cammarota, Giovanni; Gasbarrini, Antonio.

In: Nutrients, Vol. 10, No. 8, 1074, 12.08.2018.

Research output: Contribution to journalReview article

@article{088aa413365e473ba8fdb7abad3603ce,
title = "Bacillus clausii for the treatment of acute diarrhea in children: A systematic review and meta-analysis of randomized controlled trials",
abstract = "Acute diarrhea is a burdensome disease with potentially harmful consequences, especially in childhood. Despite its large use in clinical practice, the efficacy of the probiotic Bacillus clausii in treating acute childhood diarrhea remains unclear. Our objective was to systematically review the efficacy of Bacillus clausii in the treatment of acute childhood diarrhea. The following electronic databases were systematically searched up to October 2017: MEDLINE (via PubMed/OVID), EMBASE (via OVID), Cochrane Central Database of Controlled Trials (via CENTRAL), Google Scholar, and ClinicalTrials.gov. Only randomized controlled trials were included. The overall effect for the meta-analysis was derived by using a random effects model. Six randomized controlled trials (1298 patients) met the eligibility criteria. Data arising from pooled analysis showed that Bacillus clausii significantly reduced the duration of diarrhea (mean difference = −9.12 h; 95{\%} confidence interval [CI]: −16.49 to −1.75, p = 0.015), and the duration of hospitalization (mean difference = −0.85 days; 95{\%} CI: −1.56 to −0.15, p = 0.017), compared with control. There was a trend of decreasing stool frequency after Bacillus clausii administration compared with the control group (mean difference = −0.19 diarrheal motions; 95{\%} CI: −0.43 to −0.06, p = 0.14). Bacillus clausii may represent an effective therapeutic option in acute childhood diarrhea, with a good safety profile.",
keywords = "Acute diarrhea, Bacillus clausii, Children, Efficacy, Randomized controlled trials",
author = "Gianluca Ianiro and Gianenrico Rizzatti and Manuel Plomer and Loris Lopetuso and Franco Scaldaferri and Francesco Franceschi and Giovanni Cammarota and Antonio Gasbarrini",
year = "2018",
month = "8",
day = "12",
doi = "10.3390/nu10081074",
language = "English",
volume = "10",
journal = "Nutrients",
issn = "2072-6643",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Bacillus clausii for the treatment of acute diarrhea in children

T2 - A systematic review and meta-analysis of randomized controlled trials

AU - Ianiro, Gianluca

AU - Rizzatti, Gianenrico

AU - Plomer, Manuel

AU - Lopetuso, Loris

AU - Scaldaferri, Franco

AU - Franceschi, Francesco

AU - Cammarota, Giovanni

AU - Gasbarrini, Antonio

PY - 2018/8/12

Y1 - 2018/8/12

N2 - Acute diarrhea is a burdensome disease with potentially harmful consequences, especially in childhood. Despite its large use in clinical practice, the efficacy of the probiotic Bacillus clausii in treating acute childhood diarrhea remains unclear. Our objective was to systematically review the efficacy of Bacillus clausii in the treatment of acute childhood diarrhea. The following electronic databases were systematically searched up to October 2017: MEDLINE (via PubMed/OVID), EMBASE (via OVID), Cochrane Central Database of Controlled Trials (via CENTRAL), Google Scholar, and ClinicalTrials.gov. Only randomized controlled trials were included. The overall effect for the meta-analysis was derived by using a random effects model. Six randomized controlled trials (1298 patients) met the eligibility criteria. Data arising from pooled analysis showed that Bacillus clausii significantly reduced the duration of diarrhea (mean difference = −9.12 h; 95% confidence interval [CI]: −16.49 to −1.75, p = 0.015), and the duration of hospitalization (mean difference = −0.85 days; 95% CI: −1.56 to −0.15, p = 0.017), compared with control. There was a trend of decreasing stool frequency after Bacillus clausii administration compared with the control group (mean difference = −0.19 diarrheal motions; 95% CI: −0.43 to −0.06, p = 0.14). Bacillus clausii may represent an effective therapeutic option in acute childhood diarrhea, with a good safety profile.

AB - Acute diarrhea is a burdensome disease with potentially harmful consequences, especially in childhood. Despite its large use in clinical practice, the efficacy of the probiotic Bacillus clausii in treating acute childhood diarrhea remains unclear. Our objective was to systematically review the efficacy of Bacillus clausii in the treatment of acute childhood diarrhea. The following electronic databases were systematically searched up to October 2017: MEDLINE (via PubMed/OVID), EMBASE (via OVID), Cochrane Central Database of Controlled Trials (via CENTRAL), Google Scholar, and ClinicalTrials.gov. Only randomized controlled trials were included. The overall effect for the meta-analysis was derived by using a random effects model. Six randomized controlled trials (1298 patients) met the eligibility criteria. Data arising from pooled analysis showed that Bacillus clausii significantly reduced the duration of diarrhea (mean difference = −9.12 h; 95% confidence interval [CI]: −16.49 to −1.75, p = 0.015), and the duration of hospitalization (mean difference = −0.85 days; 95% CI: −1.56 to −0.15, p = 0.017), compared with control. There was a trend of decreasing stool frequency after Bacillus clausii administration compared with the control group (mean difference = −0.19 diarrheal motions; 95% CI: −0.43 to −0.06, p = 0.14). Bacillus clausii may represent an effective therapeutic option in acute childhood diarrhea, with a good safety profile.

KW - Acute diarrhea

KW - Bacillus clausii

KW - Children

KW - Efficacy

KW - Randomized controlled trials

UR - http://www.scopus.com/inward/record.url?scp=85051851675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051851675&partnerID=8YFLogxK

U2 - 10.3390/nu10081074

DO - 10.3390/nu10081074

M3 - Review article

VL - 10

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 8

M1 - 1074

ER -